AHL Partners’s Pfizer PFE Stock Holding History

AHL Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$5.59M	Sell	162,596 -72,894	-31%	-$2.49M	0.09%	452
2017 Q3	$7.98M	Buy	235,490 +75,473	+47%	+$2.43M	0.14%	244
2017 Q2	$5.1M	Buy	160,017 +61,795	+63%	+$1.95M	0.11%	343
2017 Q1	$3.19M	Buy	98,222 +26,205	+36%	+$826K	0.07%	495
2016 Q4	$2.22M	Buy	72,017 +24,313	+51%	+$742K	0.07%	480
2016 Q3	$1.53M	Buy	47,704 +17,142	+56%	+$573K	0.06%	459
2016 Q2	$1.02M	Buy	+30,562	New	+$975K	0.06%	436
2015 Q4	–	Sell	-21,905	Closed	-$653K	–	754
2015 Q3	$653K	Sell	21,905 -148,356	-87%	-$4.76M	0.1%	278
2015 Q2	$5.42M	Sell	170,261 -4,340	-2%	-$141K	0.22%	143
2015 Q1	$5.76M	Buy	174,601 +80,178	+85%	+$2.55M	0.23%	113
2014 Q4	$2.79M	Buy	94,423 +75,838	+408%	+$2.17M	0.14%	274
2014 Q3	$521K	Buy	+18,585	New	+$522K	0.04%	474

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AHL Partners's PFE Position: Q4 2017 in Review

AHL Partners reduced its Pfizer (PFE) stake by 31% in Q4 2017, selling an estimated $2.49M and leaving 162,596 shares worth $5.59M. The position accounts for 0.09% of the portfolio, ranked #452.

AHL Partners first reported a position in PFE in Q3 2014 and has held it in 12 quarters since. The position peaked at $7.98M in Q3 2017. 2,243 funds tracked by Wall St. Rank hold PFE as of Q4 2017.

AHL Partners held 162,596 shares of Pfizer worth $5.59M as of Q4 2017.
AHL Partners sold 72,894 Pfizer shares in Q4 2017, an estimated $2.49M.
Pfizer made up 0.09% of AHL Partners's portfolio in Q4 2017, its #452 holding.
AHL Partners first reported a position in Pfizer in Q3 2014 and has held it in 12 quarters since.
AHL Partners's Pfizer position peaked at $7.98M in Q3 2017.
2,243 funds tracked by Wall St. Rank held Pfizer as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.